47 results on '"Muñoz Torrico, Marcela"'
Search Results
2. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
3. Treatment of Drug-Susceptible Tuberculosis
4. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
5. Rehabilitation, optimized nutritional care, and boosting host internal milieu to improve long-term treatment outcomes in tuberculosis patients
6. Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
7. Exploring COX-2 inhibitors in tuberculosis: A whole-blood model approach for immune response and adjunt therapy evaluation
8. Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis
9. Diabetes is Associated With Severe Adverse Events in Multidrug-Resistant Tuberculosis
10. La diabetes se asocia con reacciones adversas graves en la tuberculosis multirresistente
11. Classifying new anti-tuberculosis drugs: rationale and future perspectives
12. Rapid Identification of Drug Resistance and Phylogeny in M. tuberculosis, Directly from Sputum Samples
13. Sex-Dependent Differential Expression of Lipidic Mediators Associated with Inflammation Resolution in Patients with Pulmonary Tuberculosis
14. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network
15. A bioinformatics pipeline for Mycobacterium tuberculosis sequencing that cleans contaminant reads from sputum samples
16. Oxidative Stress and Inflammatory Mediators in Exhaled Breath Condensate of Patients with Pulmonary Tuberculosis. A Pilot Study with a Biomarker Perspective
17. CXCL17 Is Dispensable during Hypervirulent Mycobacterium tuberculosis HN878 Infection in Mice
18. Altered Microbial Composition of Drug-Sensitive and Drug-Resistant TB Patients Compared with Healthy Volunteers
19. Expression of Surfactant protein D (SP-D) distinguishes severe pandemic influenza A(H1N1) from COVID-19
20. Additional file 1 of Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time
21. Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019
22. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
23. Screening for tuberculosis in migrants: a survey by the global tuberculosis network
24. Phenotype of Peripheral NK Cells in Latent, Active, and Meningeal Tuberculosis
25. Malnutrition and tuberculosis: the gap between basic research and clinical trials
26. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
27. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020
28. Antigens of Mycobacterium tuberculosis Stimulate CXCR6+ Natural Killer Cells
29. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
30. S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis
31. Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts.
32. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
33. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
34. Fatores de risco para tuberculose: diabetes, tabagismo, álcool e uso de outras drogas
35. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs
36. Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond
37. Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis
38. Efecto del polimorfismo -197GA en la producción de IL-17A en respuesta a cepas hipervirulentas de M. tuberculosis
39. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?
40. Fatores de risco para tuberculose: diabetes, tabagismo, álcool e uso de outras drogas.
41. Tuberculosis sequelae assessment and rehabilitation
42. Clinical cases
43. Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees
44. La respuesta de la unidades de terapia intensiva frente a la pandemia de influenza AH1N1 2009: la experiencia en Chiapas, México
45. Post-tuberculosis lung disease: a comparison of Brazilian, Italian, and Mexican cohorts.
46. Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network.
47. [The response of the intensive care units during the influenza A H1N1 pandemic: the experience in Chiapas, Mexico].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.